Trials / Completed
CompletedNCT02148380
Combination of Chemotherapy and Gefitinib as First-line Treatment
Combination of Chemotherapy and Gefitinib as First-line Treatment of Patients With Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomised Controlled Trial
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 121 (actual)
- Sponsor
- Baohui Han · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The results of fastact2 show that chemotherapy plus erlotinib significantly prolonged PFS and OS of patients with NSCLC. However, outcome of the combination therapy are similar to those reported in several trials of single-agent EGFR TKIs. So which is the optimal first-line treatment for patients who harbored a sensitive EGFR mutation? The investigators need a head-to-head study to reply.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pemetrexed plus carboplatin | |
| DRUG | gefitinib |
Timeline
- Start date
- 2014-05-01
- Primary completion
- 2014-12-01
- Completion
- 2015-12-01
- First posted
- 2014-05-28
- Last updated
- 2016-04-20
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02148380. Inclusion in this directory is not an endorsement.